To Assess SHR0302 Oral Solutions and Tablets in Healthy Subjects Clinical Studies of Relative Bioavailability

Graft-versus-host Disease Clinical Trial

Official title:

To Assess SHR0302 Oral Solutions and Tablets in Healthy Subjects Clinical Studies of Relative Bioavailability (Single-center, Random, Open, Crossed)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05856058
• Other study ID #: SHR0302-112
• Status: Completed
• Phase: Phase 1
• Start date: May 29, 2023
• Est. completion date: October 9, 2023

Study information

• Verified date: December 2023
• Source: Jiangsu HengRui Medicine Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To assess the relative bioavailability of SHR0302 oral solution and tablet in healthy subjects.

To assess the safety and tolerability of a single dose of SHR0302 oral solution and tablet.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 16
• Est. completion date: October 9, 2023
• Est. primary completion date: July 3, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

1. Voluntarily sign the informed consent form before the start of the activities related to the trial, and be able to understand the procedures and methods of the trial, and be willing to strictly abide by the clinical trial protocol to complete the trial;

2. Age 18~45 years old (including both end values, subject to the signing of informed consent), healthy male;

3. Weight = 50 kg, and body mass index (BMI): 19~26 kg/m2 (including both end values);

4. Sign the informed consent form and agree to use non-pharmacological effective contraception within 60 days after the last dose of the test drug.

Exclusion Criteria:

1. Those who have a history of tobacco addiction within 3 months before signing the informed consent form (an average of 5 cigarettes smoked > per day), or those who cannot stop using any tobacco products during the study;

2. Those who consumed an average of more than 25 g of alcohol per day (e.g., 750 mL of beer, 250 mL of wine, or 50 mL of liquor) per day in the 3 months prior to signing the informed consent form, or who could not stop using any alcohol-containing products during the study, or who had a positive alcohol breath test at screening;

3. Eating any drink or food containing grapefruit within 7 days before randomization; or eat any beverage or food containing methylxanthines, such as coffee, tea, cola, chocolate, etc., within 2 days before randomization;

4. Allergic constitution, or suspected allergy to any ingredient in SHR0302 drug;

5. Drug abusers, or positive urine drug abuse screening at screening, including:

morphine, meth (methamphetamine), ketamine, cocaine, ecstasy (MDMA - Methylenedioxymethamphetamine), marijuana (tetrahydrocannabinol acid);

6. Have any history of clinically serious diseases or diseases or conditions that the investigator believes may affect the test results, including but not limited to circulatory, endocrine, nervous system, digestive system, urinary system or blood, immune, psychiatric and metabolic diseases;

7. Those who have a history of tuberculosis within 6 months before signing the informed consent form; or those with a positive ?-interferon release test (IGRA) within 4 weeks prior to randomization;

8. 12-lead ECG QTcF > 450 ms or other abnormalities judged clinically significant by the investigator in the first 4 weeks of randomization;

9. Vital signs, physical examination, laboratory tests, abdominal ultrasound or chest imaging in the first 4 weeks of randomization suggest that there are abnormalities that are judged to be clinically significant by the investigator;

10. Within 4 weeks before randomization, hepatitis B surface antigen (HBsAg) positive, or anti-hepatitis C virus (HCV) antibody positive, or human immunodeficiency virus (HIV) antibody positive, or syphilis antibody positive;

11. Infections (viral, bacterial, fungal, parasitic infections) that require systemic antimicrobial therapy within 4 weeks of randomization;

12. Use of any prescription drug, over-the-counter drug, Chinese herbal medicine or dietary supplement within 2 weeks prior to randomization;

13. Systemic therapy with inhibitors or inducers of cytochrome P450 3A4 enzyme (CYP3A4) within 4 weeks before randomization (see Annex 2 for details);

14. Those who participated in any drug clinical trial and took the experimental drug within 3 months before randomization (calculated from the start time of the last visit of the last trial) (if the 5 half-lives of the experimental drug exceed 3 months, the time of the 5 half-lives shall prevail);

15. Have received BCG vaccine within 12 months prior to randomization; or vaccination or exposure to other live vaccines or live attenuated vaccines within the first 3 months of randomization; or those who plan to be vaccinated during the trial;

16. Those who have undergone any surgery within the previous 3 months of randomization, or who have not recovered after surgery, or who may have surgery or hospitalization plans during the estimated trial period;

17. Those who donate blood (or lose blood) within 3 months of randomization and donate blood (or blood loss) in an amount = 400 mL, or receive blood transfusion;

18. The investigator judges that the subject has a situation that affects the absorption, distribution, metabolism and excretion of drugs, or has other factors that are not suitable to participate in this study.

Related Conditions & MeSH terms

• Graft vs Host Disease
• Graft-versus-host Disease

Intervention

Drug:
• SHR0302
SHR0302 oral solution 1 time, SHR0302 tablets 1 time

Locations

Country	Name	City	State
China	Beijing Hospital	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Jiangsu HengRui Medicine Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	SHR0302 and its main Pk parameter, AUC0-t		day 1 to 8
Primary	SHR0302 and its main Pk parameter, AUC0-inf		day 1 to 8
Primary	SHR0302 and its main Pk parameter, Cmax		day 1 to 8
Primary	Relative bioavailability (F%) value between SHR0302 oral solution and SHR0302 tablet: F% = AUC0-t (oral solution) / AUC0-t (tablet) ×100%		day 1 to 8
Secondary	SHR0302 and its main Pk parameter, Tmax (SHR0302 only)		day 1 to 8
Secondary	SHR0302 and its main Pk parameter, t1/2 (SHR0302 only)		day 1 to 8
Secondary	SHR0302 and its main Pk parameter, CL/F (SHR0302 only)		day 1 to 8
Secondary	SHR0302 and its main Pk parameter, Vz/F (SHR0302 only)		day 1 to 8
Secondary	Adverse events		day 1 to 12